# PH-HFpEF FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/ph-hfpef

> 1 upcoming FDA catalyst in PH-HFpEF: TX2100 (TECX) on early 2027 (trial start).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for PH-HFpEF?

1 upcoming FDA catalyst in PH-HFpEF: TX2100 (TECX) on early 2027 (trial start). SEC Form 10-K: "This includes topline results from our TX45 APEX Phase 2 clinical trial in patients with PH-HFpEF expected in 2026, topline results from our TX2100 Phase 1a clinical trial expected in the fourth quarter of 2026, the potential initiation of a TX2100 Phase 1b clinical trial in patients with severe HHT, and plans to initiate a TX2100 Phase 2 clinical trial in patients with moderate to severe HHT in early 2027." [Calendar and source filings](https://sec-api.dev/indications/ph-hfpef)

Source: SEC Form 10-K, accession 0001193125-26-076793, https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/tecx-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-09-29. Cite: https://sec-api.dev/indications/ph-hfpef#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2025 | [Levosimendan trial start](https://sec-api.dev/pdufa/levosimendan) | TENX | PH-HFpEF | scheduled | "We intend to use the net proceeds from the August 2024 and March 2025 Offerings to advance our Phase 3 oral levosimendan program, by completing our ongoing Phase 3 LEVEL study and initiating a second planned global Phase 3 study, LEVEL-2." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/34956/000095017025044398/tennx-20241231.htm)) |
| December 17, 2025 | [Levosimendan trial start](https://sec-api.dev/pdufa/levosimendan) | TENX | PH-HFpEF | completed | "On December 17, 2025, we also announced that we initiated LEVEL-2 (NCT07288398), the second registrational study of TNX-103 in patients with PH-HFpEF." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm)) |
| early 2027 | [TX2100 trial start](https://sec-api.dev/pdufa/tx2100) | TECX | PH-HFpEF | scheduled | "This includes topline results from our TX45 APEX Phase 2 clinical trial in patients with PH-HFpEF expected in 2026, topline results from our TX2100 Phase 1a clinical trial expected in the fourth quarter of 2026, the potential initiation of a TX2100 Phase 1b clinical trial in patients with severe HHT, and plans to initiate a TX2100 Phase 2 clinical trial in patients with moderate to severe HHT in early 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/tecx-20251231.htm)) |

## Drugs

- [Levosimendan](https://sec-api.dev/pdufa/levosimendan) (TNXP)
- [TX2100](https://sec-api.dev/pdufa/tx2100) (TECX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/ph-hfpef.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PH-HFpEF FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/ph-hfpef

```bibtex
@misc{secapidev_indications_ph_hfpef_20261116,
  title        = {PH-HFpEF FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/ph-hfpef}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_ph_hfpef_20261116","title":"PH-HFpEF FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/ph-hfpef","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
